Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Metabolic · Incretin

Liraglutide

FDA-approved daily GLP-1 receptor agonist.

FDA-Approved

Plain-Language Label Highlights

Brand names: Victoza, Saxenda

What it's approved for

Type 2 diabetes (Victoza) and chronic weight management (Saxenda).

A daily injection that mimics a gut hormone to lower blood sugar and reduce appetite.

Boxed Warning

Thyroid C-cell tumor risk in rodents — avoid with medullary thyroid cancer or MEN 2.

Common side effects
  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • Headache
Serious risks to know
  • Pancreatitis
  • Gallbladder disease
  • Kidney injury
  • Low blood sugar (with insulin/sulfonylurea)
Who should avoid or use with extra caution
  • Medullary thyroid cancer history
  • MEN 2 syndrome

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

A daily GLP-1 receptor agonist with a fatty-acid side chain that enables albumin binding and ~13-hour half-life. Mechanism mirrors semaglutide at shorter duration: enhanced glucose-dependent insulin release, slowed gastric emptying, and central appetite suppression.

Research Areas

Type 2 diabetes (Victoza)
Chronic weight management (Saxenda)
Cardiovascular risk reduction in T2D

Common Research Protocols

Daily subcutaneous clinical use

Stepwise dose escalation in approved indications.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]New England Journal of Medicine·2016

Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)

Significant reduction in major adverse cardiovascular events vs placebo.

Important Considerations

  • FDA-approved; requires prescription and physician oversight.
  • GI side effects, pancreatitis risk, gallbladder events.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Liraglutide

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.